BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29858106)

  • 21. [Use of sFlt-1/PlGF ratio in preeclampsia : a monocentric retrospective analysis].
    Verbeurgt L; Chantraine F; De Marchin J; Minon JM; Nisolle M
    Rev Med Liege; 2017 Sep; 72(9):393-398. PubMed ID: 28892314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.
    Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO
    BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
    Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
    Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic plasma exchange and dextran-sulfate plasma adsorption as extracorporeal treatments of extremely preterm preeclampsia with fetal growth restriction.
    Gubensek J; Ponikvar R; Premru Srsen T; Fabjan Vodusek V; Moertl MG; Lucovnik M
    J Clin Apher; 2021 Aug; 36(4):595-605. PubMed ID: 33847403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective evaluation of established cut-off values for the sFlt-1/PlGF ratio for predicting imminent delivery in preeclampsia patients.
    Enengl S; Mayer RB; Le Renard PE; Shebl O; Arzt W; Oppelt P
    Pregnancy Hypertens; 2020 Jan; 19():143-149. PubMed ID: 32000115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®.
    Dröge LA; Höller A; Ehrlich L; Verlohren S; Henrich W; Perschel FH
    Pregnancy Hypertens; 2017 Apr; 8():31-36. PubMed ID: 28501276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Assessment of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for the Diagnostic and the Prognosis of Preeclampsia in the Second Trimester.
    Chelli D; Hamdi A; Saoudi S; Jenayah AA; Zagre A; Jguerim H; Bedis C; Sfar E
    Clin Lab; 2016 Oct; 62(10):1927-1932. PubMed ID: 28164532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
    Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
    Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction.
    Schoofs K; Grittner U; Engels T; Pape J; Denk B; Henrich W; Verlohren S
    J Perinat Med; 2014 Jan; 42(1):61-8. PubMed ID: 23929878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia.
    Álvarez-Fernández I; Prieto B; Rodríguez V; Ruano Y; Escudero AI; Álvarez FV
    Clin Chim Acta; 2016 Dec; 463():150-157. PubMed ID: 27983995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany.
    Schlembach D; Hund M; Schroer A; Wolf C
    BMC Health Serv Res; 2018 Aug; 18(1):603. PubMed ID: 30081904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An intermediate sFlt-1/PlGF ratio indicates an increased risk for adverse pregnancy outcome.
    Hoffmann J; Ossada V; Weber M; Stepan H
    Pregnancy Hypertens; 2017 Oct; 10():165-170. PubMed ID: 29153672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia.
    Triunfo S; Crovetto F; Crispi F; Rodriguez-Sureda V; Dominguez C; Nadal A; Peguero A; Gratacos E; Figueras F
    Placenta; 2016 Jun; 42():44-50. PubMed ID: 27238713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating angiogenic factors and the risk of preeclampsia.
    Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
    N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia.
    Matin M; Mörgelin M; Stetefeld J; Schermer B; Brinkkoetter PT; Benzing T; Koch M; Hagmann H
    Hypertension; 2020 Oct; 76(4):1176-1184. PubMed ID: 32623922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
    Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
    Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.